Glenmark Life Sciences Ltd (GLS)

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Share Price: ₹841.15 per share as on 02 May, 2024 04:01 PM
Market Capitalisation: ₹10,156.28Cr as of today
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha